One More Approval for Merck’s Keytruda

On Wednesday, a day after Keytruda got the thumbs up for cervical cancer, the drug was approved for treatment of a rare form of non-Hodgkins lymphoma patients who cancer returned after at least two previous treatment lines. Last year, Keytruda also got an indication for classical Hodgkin lymphoma.

• Source: Fierce Pharma
• 717
• June 15, 2018